Protocol Information

If you are interested in learning more about this study, please call or email the contact person below

Title An Open-Label, Proof of Concept Study Designed to Evaluate the Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients with Newly Diagnosed, Moderate to Extensive Bullous Pemphigoid. Immune/BRT/BP-01
Description Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid


Study visits will be in downtown, Buffalo.
Objective This is an open-label, proof-of-concept, single group study in adult patients with newly diagnosed, moderate to extensive Bullous Pemphigoid. The primary objective is to evaluate the safety of bertilimumab in patients with newly diagnosed, moderate to extensive BP.

Keywords: Bullous Pemphigoid, Bertilimumab, autoimmune
Principal Investigator SINHA, ANIMESH
Age Group Adult
Drugs Involved
Clinical Trials.gov http://www.clinicaltrials.gov/ct2/show/NCT02226146/
Status Open
Key Eligibility Age 60 years or older
Newly diagnosed Bullous Pemphigoid
Disease Group Autoimmune Disorders; Skin/Dermatology
Treatment Intravenous injection of Bertilimumab
Contact Alba Posligua
716-645-8990
albaposl@buffalo.edu